And heres the thing they already have Phase 2b numbers on the board (Dec 2025): 11.3% placebo-adjusted weight loss at 120 mg over 36 weeks, and a pretty striking 15.3% at 240 mg with the curve still bending down at 44 weeks in the OLE
However, patients who maintain the healthy eating and exercise patterns developed during treatment typically keep off most of their weight loss
To view or add a comment, sign in Every FPGEE candidate should be able to answer this in seconds: a patient with reduced-EF heart failure is on an ARNI, a beta-blocker, and an SGLT2 inhibitor what completes their guideline-directed therapy
This range falls within the average carnitine concentration in plasma (Indiveri et al., 2010
Scortegagna M, Ruller C, Feng Y, Lazova R, Kluger H, Li JL et al
GHRPs act through a GHRH-independent pathway they stimulate GH secretion by a different molecular route than GHRH analogues